Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase
{{output}}
The recent surge in global monkeypox (mpox) outbreaks highlights the critical need for developing antiviral agents targeting orthopoxvirus infections. Ibrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor initially approved by the FDA in 2013 for treat... ...
